topotecan has been researched along with Adenocarcinoma, Endometrioid in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fusco, N; Haba, P; Rodriguez, M; Rose, PG; Smrekar, M | 1 |
| Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D | 1 |
| Camporeale, A; Cormio, G; De Mitri, P; Gissi, F; Leone, L; Loizzi, V; Putignano, G; Selvaggi, L | 1 |
| Beshara, N; Faught, W; Fung Kee Fung, M | 1 |
1 trial(s) available for topotecan and Adenocarcinoma, Endometrioid
| Article | Year |
|---|---|
A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Prognosis; Survival Rate; Topotecan | 2008 |
3 other study(ies) available for topotecan and Adenocarcinoma, Endometrioid
| Article | Year |
|---|---|
[Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Luminescent Measurements; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Topotecan | 2010 |
Long-term topotecan therapy in recurrent or persistent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Disease Progression; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2011 |
The role of topotecan as second-line therapy in patients with recurrent ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Endometrioid; Cystadenocarcinoma, Papillary; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Medical Records; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Topotecan | 2002 |